Ex Vivo Permeation of Carprofen Vehiculated by PLGA Nanoparticles through Porcine Mucous Membranes and Ophthalmic Tissues

dc.contributor.author
Gómez, Lidia
dc.contributor.author
Parra Coca, Alexander
dc.contributor.author
Calpena Campmany, Ana Cristina
dc.contributor.author
Gimeno Sandig, Álvaro
dc.contributor.author
Gómez de Aranda Pulgarín, Inmaculada
dc.contributor.author
Boix Montañés, Antonio de Pádua
dc.date.issued
2020-05-21T07:22:00Z
dc.date.issued
2020-05-21T07:22:00Z
dc.date.issued
2020-02-18
dc.date.issued
2020-05-21T07:22:01Z
dc.identifier
2079-4991
dc.identifier
https://hdl.handle.net/2445/161798
dc.identifier
699241
dc.identifier
30279564
dc.description.abstract
(1) Background: Carprofen (CP), 2-(6-chlorocarbazole) propionic acid, is used as an anti-inflammatory, analgesic and anti-pyretic agent and it belongs to the family of non-steroidal anti-inflammatory drugs (NSAIDs). CP has some adverse reactions in systemic administration; for this reason, topical administration with CP nanoparticles (CP-NPs) can be an optimal alternative. The main objective of this work is the investigation of ex vivo permeation of CP through different types of porcine mucous membranes (buccal, sublingual and vaginal) and ophthalmic tissues (cornea, sclera and conjunctiva) to compare the influence of CP-NPs formulation over a CP solution (CP-Solution). (2) Methods: The ex vivo permeation profiles were evaluated using Franz diffusion cells. Furthermore, in vivo studies were performed to verify that the formulations did not affect the cell structure and to establish the amount retained (Qr) in the tissues. (3) Results: Permeation of CP-NPs is more effective in terms of drug retention in almost all tissues (with the exception of sclera and sublingual). In vivo studies show that neither of the two formulations affects tissue structure, so both formulations are safe. (4) Conclusions: It was concluded that CP-NPs may be a useful tool for the topical treatment of local inflammation in veterinary and human medicine.
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI
dc.relation
Reproducció del document publicat a: https://doi.org/10.3390/nano10020355
dc.relation
Nanomaterials, 2020, vol. 10, num. 2, p. 355
dc.relation
https://doi.org/10.3390/nano10020355
dc.rights
cc-by (c) Gomez, Lidia et al., 2020
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject
Nanopartícules
dc.subject
Solucions (Farmàcia)
dc.subject
Sistemes d'alliberament de medicaments
dc.subject
Agents antiinflamatoris
dc.subject
Malalties dels animals
dc.subject
Porc
dc.subject
Assaigs clínics
dc.subject
Nanoparticles
dc.subject
Solutions (Pharmacy)
dc.subject
Drug delivery systems
dc.subject
Antiinflammatory agents
dc.subject
Animal diseases
dc.subject
Swine
dc.subject
Clinical trials
dc.title
Ex Vivo Permeation of Carprofen Vehiculated by PLGA Nanoparticles through Porcine Mucous Membranes and Ophthalmic Tissues
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.